Protagonist Therapeutics, Inc (PTGX): Total Assets
$668.19M
As of 2025-12-31
$885.54M
As of 2026-06-30
+39.2%
3-year compound annual growth
+15.5%
5-year compound annual growth
+46.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $668.19M | -10.3% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $744.73M | +108.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $357.95M | +44.4% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $247.93M | -28.7% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $347.69M | +7.2% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $324.47M | +109.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $154.92M | +11.1% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $139.47M | -14.8% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $163.73M | +74.2% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $93.99M | +533.1% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $14.85M | n/a | 2017-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $25.34M | +1.8% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $638.50M | +81.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗